Clinical Medicine and Health Research Journal (CMHRJ)
Volume 01, Issue 03, November-December, 2021
Page No. 69-73

Research Article

Body Immunity and Resistance to (COVID-19) Corona Virus

Hayfaa Mahmood Fahad[1], Mohammed Hussein Mushrif[2], Sahar Taha Hatif[3]

[1,2,3] College of Medicine , AL -Iraqia University

Received: 14 September, 2021 Accepted: 25 October, 2021 Published: 30 November 2021

Abstract:

The invulnerable framework secures against infections and sicknesses and produces antibodies to kill microbes. Extremely severe respiratory illness 2 Covid (SARS-CoV-2) is the causative specialist of the continuous coronavir infection sickness 2019 (COVID-19) pandemic. This survey gives an outline of the resistant framework, how it works, and its instrument to battle infection. Different kinds of possible difficulties for the immunes framework are likewise examined. Food to devour and stay away from are recommended, and actual exercise is empowered.

KeyWord: Immunity system, COVID-19, monoclonal antibodies, patients, infections in humans.

Introduction

COVID-19 individuals' white platelet counts fluctuate between leukopenia, leukocytosis, and lymphopenia. In patients with the contamination, lymphopenia and decreased lymphocyte incorporation revealed a vulnerable figure[1]. Antigen-presenting cell (APC) function is altered after SARS-CoV infection and inhibited DC migration results in impaired T cell preparation. This will result in a reduction in the number of contaminated unambiguous T cells in the lungs. TCR commitment with the peptide-MHC complex triggers T cell initiation, multiplication, and relocation to the sullied site . Cytotoxic lymphocytes (CTLs) and normal executioner (NK) cells are significant for viral pollution in all cases, and their abuse could fuel sickness seriousness[2]. In COVID-19 patients, indisputably the quantity of NK and CTLs is decreased, which is because of their drowsiness and upregulation of the NK inhibitory receptor CD94/NK pack 2 segment A (NKG2A) (81 .(

SARS-S CoV's and N proteins incorporate immunogenic epitopes that CD4 and CD8 T cells perceive. IgM and IgG are amazing antibodies in SARS, and IgM was recognized in calm's blood 3–6 days after the ailment, while IgG was distinguished following 8 days (90, 91). This recommends that a period of IgG antibodies might be needed to give a more drawn-out term cognizant work.(3) [

Cytotoxic particles, for example, granzyme B straightforwardly kill ruined epithelial cells and help with getting out the microorganism. Effector cytokines like IFN-γ unmistakably obstruct viral replication and further foster antigen show[4]. One of the vital instruments for ARDS actuated by SARS-CoV-2 is the cytokine storm, the destructive uncontrolled central provocative reaction coming to fruition because of the presence of a huge load of consistent bursting cytokines. This might have a prognostic driving force for perceiving people in danger of making authentic turmoil[5]. Discretionary hemophagocytic lymphohistiocytosis (sHLH) is a hyperinflammatory issue described by a fulminant and conceivably deadly hypercytokinemia. Hyperinflammation, as estimated by raised ferritin, low platelet counts, and erythrocyte sedimentation rate, ought to be surveyed in all patients with strange COVID-19. Steroids, intravenous immunoglobulin, express cytokine barricade (e.g., anakinra or tocilizumab), and JAK restraint (107–111) are for the most part compulsory choices, and the results are probably going to be promising .

The presence of metabolic equilibrium condition/imposingness, and especially its catches, like diabetes and hypertension, is associated with a drawn-out penchant to develop a more affirmed disease[6]. Patients with past cardiovascular metabolic illnesses in like way have a more veritable danger of making ridiculous sickness featuring the way that the presence of comorbidities generally impacts the figure of patients with COVID-19 .

Early examination of blood tests using scRNA-seq has uncovered a separated IFN-empowered response and HLA class II downregulation[7]. In subjects with great respiratory disappointment requiring mechanical ventilation, a wonderful B cell-impelled granulocyte people were seen. streaming leukocytes don't present clear levels of remarkable for ignitable cytokines and chemokines recommending that the COVID-19 cytokine storm is driven by cells inside the lung. The appraisal of the host safe response from absurd and recuperating individuals will give nuclear pieces of information into parts by which we may engage protection and critical length safe memory[8].

Definition of COVID-19

Covid (CoV) are pleomorphic RNA illnesses with crown-

outlined peplomers going in size from 80 to 160 nanometers with a genome of 27–32 kilobytes. They can debase an arrangement of hosts, including individuals and a few different vertebrates, causing issues of the respiratory, gastrointestinal, hepatic, cardiovascular, kidney, and neurologic systems. Right, when present in people and various species, CoVs have a high change rate and a high ability to function as microorganisms, thinking about a wide extent of clinical applications[9,10].

History of COVID-19

A new Coronavirus (nCoV) was discovered in the Huanan wet food market in Wuhan, Hubei Province, China, in December 2019. SARS-CoV-2 was called after the nCoV that spread along these lines from the site of an important scene in China. In the last two decades, Covids have created three scourges: COVID-19, SARS, and Middle East respiratory disease (MERS). There are currently no antiviral drugs available. Efforts to create antiviral medicines and a neutralizer are urgently needed.[11,12]

The principal events of Covid illness 2019 (COVID-19) reasonably happened from a zoonotic transmission in China. There is no enlisted treatment or immunization for this hardship. The use of an antiviral medication called Favilavir as a treatment has been upheld by China [13,14].

Process of the immune system in the human body

The body contains the organs of the resistant construction, which gets against infections. It acknowledges a basic part to remain mindful of flourishing and pathogenesis and protections the body from damaging substances, microorganisms, and cell changes. The safe cells gather, work, and serve to challenge antigens in lymph community focuses and the spleen's compartments. Precisely when they are in the circulatory system, they are moved to tissues all through the body[15].

Impacts of Covid-19 on the human body

Coronavirus is a RNA illness with a crown-like appearance. It is conferred through respiratory drops from hacking and wheezing and enters the nasal design by taking in and begins reiterating. The illness will be fragile for 80% of patients and generally limited to the upper and planning flying courses. Around 20% of ruined patients make pneumonic assaults and a piece of these develop exceptionally authentic defilement.

Most patients with COVD-19 were old patients in the extreme gathering, with essential infections. Age was the danger factor for patients with a serious condition, as shown by the Lasso calculation. Patients matured more seasoned than 60 years who have comorbidities are in danger of death from SARS-CoV-2 contamination[17,18].



Fig (1) Chronology of events during SARS-CoV-2 infection [16].

Mechanism of immune systems in the human body against COVID-19

There is no enlisted medication or immunization against COVID-19. The resistant framework is the best guard since it upholds the body's inherent capacity to protect against microorganisms. At the point when the body experiences microbes interestingly, the insusceptible framework can't work as expected and sickness can happen. Numerous sub-atomic and cell profiling examines are currently accessible for the investigation of the human- resistant framework. The degree of progression of instruments has expanded (e.g., polychromatic stream cytometers have improved) In the fields of genomics and proteomics, major mechanical leap forwards has likewise happened [19,20].

SARS-CoV-2 has comparable safe avoidance systems to SARS, yet an extra instrument stays unseen. Shi et al. [34] proposed some typical methodologies for the treatment of patients with COVID-19. HLA composing will give data to planning counteraction, treatment, immunization, and clinical methodologies[21,22].

Inflammatory immunopathogenesis

SARS-CoV-2 contamination and obliteration of lung cells trigger a neighborhood insusceptible reaction, enrolling macrophages and monocytes that discharge cytokines and prime versatile T and B cell reactions. Pyroptosis is a profoundly fiery type of customized cell passing that is ordinarily seen with cytopathic infections[23].



Fig (2)Potential therapeutic approaches against SARS-CoV-2 [24].

In patients with SARS-CoV-2, a useless safe reaction happens, which triggers a cytokine storm that intervenes in boundless lung irritation. Patients with the serious illness show a fundamentally higher level of CD14+CD16+ provocative monocytes infringe blood than patients with gentle sickness. Cytokine tempest can make harm the lung through exorbitant discharge of proteases and responsive oxygen species. Raised degrees of cytokines, for example, TNF can cause septic shock and multi-organ disappointment. These might bring about myocardial harm and circulatory disappointment seen in certain patients [25,26,27].

Viral disease in resistant cells, for example, monocytes and macrophages can bring about deviant cytokine creation, regardless of whether viral contamination isn't useful. Understanding the exact drivers of safe brokenness is urgent to direct the utilization of suitable immunomodulatory medicines [28,29,30]. Corticosteroids are in progress for treatment of COVID-19, albeit this class of the treatment was not suggested during the 2003 SARS pestilence another novel adjunctive treatment is cytosorb, which acts by retaining a wide range of cytokines, DAMPs ,and PAMPs [31,32].



Fig (3) . Schematic immune responses to CoVs [33].

T cell immunity

Both T and B cell reactions against SARS-CoV-2 are distinguished in the blood around a multi week after the beginning of COVID-19 indications. CD8+ T cells are significant for straightforwardly assaulting and killing infected tainted cells [34,35,36]. Despite the weakened reaction, patients who recuperated created Covid explicit memory T cells. CD4+ T cells have been conjectured to control SARS, as exhaustion of these cells in mice came about in more slow leeway of the infection from the host and severer lung aggravation. Move of SARS-CoV-explicit CD4+ and CD8 + T cells into immunodeficient mice prompted better security against a mouse-adjusted strain of the illness[37,38,39]

B cell insusceptibility

Patients with COVID-19 experience B cell reactions in the same way that T follicular aide cell reactions do, starting around a week after the side effect first appears. In patients with SARS-CoV contamination, B cell reactions commonly emerge first against the nucleocapsid (N) protein [40,41].

Expected difficulties in insusceptible framework advancement

A sound invulnerable framework has cooperative microbial homesteads and responds to destructive contamination. More often than not, the resistant framework considers a new thing and thinks of it as innocuous, yet at times, that reaction can be hazardous. An effective safe framework can recognize this [42,43,44].

Recommended food, immunization, drugs, and advantageous for the safe framework for COVID-19

Good dietary sources and hydration, according to the World Health Organization, are essential. People who follow a consistent eating schedule have a stronger immune system. Lack of healthy sustenance is perilous for patients with COVID-19 and consequently appropriate nourishment ought to be given. Alongside diet, actual work is another factor [45,46,47].

Conclusion

This Review has introduced the different systems of SARS-CoV-2 disease and COVID-19 immunopathogenesis. Controlling the fiery reaction might be pretty much as significant as focusing on the infection. Treatments restraining viral disease and guidelines of broken invulnerable reactions may synergize.

References

1. Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. [PMC free article] [PubMed] [Google Scholar]
2. Tang N.L., Chan P.K., Wong C.K. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin Chem. 2005;51:2333–2340. [PMC free article] [PubMed] [Google Scholar]
3. Hancock A.S., Stairiker C.J., Boesteanu A.C. Transcriptome analysis of infected and bystander type 2 alveolar epithelial cells during influenza A virus infection reveals in vivo Wnt pathway downregulation. J Virol. 2018;92 e01325-18. [PMC free article] [PubMed] [Google Scholar]
4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coro-navirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020 [in press]. [PubMed]
5. Mason R.J. Pathogenesis of COVID-19 from a cell

biology perspective. Eur Respir J. 2020;55 [PMC free article] [PubMed] [Google Scholar]
6. Wang D., Hu B., Hu C., Chang Hu, Zhu F., Liu X. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 [Published online 7 February 2020] [PMC free article] [PubMed] [Google Scholar]
7. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 (January) [PMC free article] [PubMed] [Google Scholar]
8. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):49. [PMC free article] [PubMed] [Google Scholar]
9. Qin Yin, Zhen Fu, Jiao Xie, Jixing Zhang. 2020. April Analysis of risk factors of severe COVID-19 patients. [Google Scholar]
10. https://www.britannica.com/science/immune-system.
11. https://www.ncbi.nlm.nih.gov/books/NBK279397/.
12. https://www.khanacademy.org/science/high-school-biology/hs-human-body-systems/hs-the-immune-system/a/hs-the-immune-system-review.
13. https://en.wikibooks.org/wiki/HumanPhysiology/TheImmuneSystem.
14. Chaussabel D., Pascual V., Banchereau J. Assessing the human immune system through blood transcriptomics. BMC Biol. 2010;8:84. [PMC free article] [PubMed] [Google Scholar]
15. https://gulfnews.com/world/3-types-of-immunity-your-best-defence-vs-coronavirus-1.1583917783603?slide=1.
16. Swatantra Kumar, Rajni Nyodu, Maurya Vimal K., Saxena Shailendra K. Coronavirus disease 2019 (COVID-19) 2020. Host immune response and immunobiology of human SARS-CoV-2 infection; pp. 43–53. [Google Scholar]
17. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. [PMC free article] [PubMed] [Google Scholar]
18. Prompetchara E., Ketloy C., Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9. [PubMed] [Google Scholar]
19. Susanna Felsenstein, Herbert Jenny A., McNamara Paul S., Hedrich Chris-tian M. COVID-19: immunology and treatment options. Clin Immunol. 2020;215 [Google Scholar]
20. Shi Y., Wang Y., Shao C. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020 [PMC free article] [PubMed] [Google Scholar]
21. Ruan Qm, Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 [PMC free article] [PubMed] [Google Scholar]
22. Ramos-Casals M., Brito-Zeron P., Lopez-Guillermo A., Khamashta M.A., Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383:1503–1516. [PubMed] [Google Scholar]
23. Karakike E., Giamarellos-Bourboulis E.J. Macrophage activation-like syn-drome: a distinct entity leading to early death in sepsis. Front Immunol. 2019;10:55. [PMC free article] [PubMed] [Google Scholar]
24. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. [PMC free article] [PubMed] [Google Scholar]
25. Puja Mehta, McAuley Daniel F., Michael Brown, Emilie Sanchez, Tat-tersall Rachel S., Manson Jessica J. COVID-16: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395 (March (10229)):P1033–034. [PMC free article] [PubMed] [Google Scholar]
26. Le Tung Thanh, Zacharias Andreadakis, Arun Kumar, Gómez Román Raúl, Stig Tollefsen, Melanie Saville. 2020. The COVID-19 vaccine development land-scape. [Google Scholar]
27. Nelson Lee, Allison McGeer. The starting line for the COVID-19 vaccine devel-opment. Lancet. 2020 [Google Scholar]
28. Mingxiang Ye, Dian Fu, Yi Ren, Faxiang Wang, Dong Wang, Fang Zhang. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020 [PMC free article] [PubMed] [Google Scholar]
29. Mair-Jenkins J., Saavedra -Campos M., Baillie J.K. The effectiveness of con-valescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. [PMC free article] [PubMed] [Google Scholar]
30. Wan Y., Shang J., Graham R. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. 2020;94 e00127–220. [PMC free article] [PubMed] [Google Scholar]
31. Hancock A.S., Stairiker C.J., Boesteanu A.C. Transcriptome analysis of infected and bystander type 2 alveolar epithelial cells during influenza A virus infection reveals in vivo Wnt pathway downregulation. J Virol. 2018;92 e01325-18. [PMC free article] [PubMed] [Google Scholar]
32. Manuel Rojas, Yhojan Rodríguezab, Monsalvea Diana M., Acosta Ampudia Yeny, Bernardo Camachoc, Esteban Gallod Juan. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020;19(July (7)) [Google Scholar]
33. Bin Zhang, Shuyi Liu, Tan Tan., Wenhui Huang, Yuhao Dong, Luyan Chen. 2020. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2

infection chest. [PMC free article] [PubMed] [Google Scholar]
34. Shen C., Wang Z., Zhao F., Yang Y., Li J., Yuan J. Treatment of 5 critically ill patients with Covid-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. [PMC free article] [PubMed] [Google Scholar]
35. Duan K., Liu B., Li C., Zhang H., Yu T., Qu J. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 [PMC free article] [PubMed] [Google Scholar]
36. Ye M., Fu D., Ren Y., Wang F., Wang D., Zhang F. Treatment with convalescent plasma for patients with COVID-19 in Wuhan, China. J Med Virol. 2020 [Google Scholar]
37. Ahn J.Y., Sohn Y., Lee S.H., Cho Y., Hyun J.H., Baek Y.J. Use of convalescent plasma therapy in two patients with COVID-19 with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020;35:e149. [PMC free article] [PubMed] [Google Scholar]
38. Soo Y.O.Y., Cheng Y., Wong R., Hui D.S., Lee C.K., Tsang K.K.S. Retrospective comparison of convalescent plasma with continuing high-dose methyl-prednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10:676–678. [PMC free article] [PubMed] [Google Scholar]
39. Cheng Y., Wong R., Soo Y.O.Y., Wong W.S., Lee C.K., Ng M.H.L. Use of conva-lescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–46. [PMC free article] [PubMed] [Google Scholar]
40. Nie Q.-H.-H., Luo X.-D.-D., Hui W.-L.-L. Advances in clinical diagnosis and treatment of severe acute respiratory syndrome world. J Gastroenterol. 2003;9:1139–1143. [PMC free article] [PubMed] [Google Scholar]
41. Yeh K.-M.-M., Chiueh T.-S.-S., Siu L.K., Lin J.-C.-C., Chan P.K.S., Peng M.-Y.-Y. Experi-ence of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56:919–922. [PMC free article] [PubMed] [Google Scholar]
42. Zhou X., Zhao M., Wang F., Jiang T., Li Y., Nie W. Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute res-piratory syndrome in Beijing area. Zhonghua Yi Xue Za Zhi. 2003;83:1018–1022. [PubMed] [Google Scholar]
43. Kong L. Letter to editor. Transfus Apher Sci. 2003;29:101. [PMC free article] [PubMed] [Google Scholar]
44. Wong V.W.S., Dai D., Wu A.K.L., Sung J.J.Y. Treatment of severe acute respiratory syndrome with convalescent plasma Hong Kong. Med J. 2003;9:199–201. [PubMed] [Google Scholar]
45. Ko J.-H.-H., Seok H., Cho S.Y., Ha Y.E., Baek J.Y., Kim S.H. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23:617–622. [PubMed] [Google Scholar]
46. van Griensven J., Edwards T., de Lamballerie X., Semple M.G., Gallian P., Baize S. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374:33–42. [PMC free article] [PubMed] [Google Scholar]